NEW TECHNOLOGY SESSION
Long-read multiomics for human disease research: an expert panel discussion
Thursday, September 17th, 9:00 AM PDT | 12:00 PM EDT | 5:00 PM GMT
NEW TECHNOLOGY SESSION
Thursday, September 17th, 9:00 AM PDT | 12:00 PM EDT | 5:00 PM GMT
Step into a new era of long-read multiomics with leading experts in human disease research
Many human diseases cannot be fully understood through a single molecular lens. Genetic variants can alter chromatin accessibility, disrupt RNA splicing, change protein expression, and ultimately drive disease biology. As a result, researchers are increasingly integrating genomic, epigenomic, transcriptomic, and proteomic data to better understand disease mechanisms and identify new therapeutic opportunities.
Long-read sequencing is enabling this next generation of multiomic research by providing highly accurate, comprehensive views of these molecular layers. In this webinar, two leading researchers will share how they are applying long-read multiomics to advance rare disease diagnostics, uncover molecular mechanisms of neurodegenerative disease, and develop AI-driven approaches for therapeutic discovery. The presentations will be followed by a live panel discussion where attendees can ask questions and hear perspectives on the future of multiomics in human disease research.
Register to learn:
SAVE YOUR SEAT
Jocelyne Bruand
Principal I Scientist, Bioinformatics, PacBio
Host
Andrew B. Stergachis, MD, PhD, FACMG
Associate Professor of Medicine and Genome Sciences, University of Washington
Evgeny Kiner, PhD
CEO & founder, NeoSplice Therapeutics
Dr. Andrew Stergachis is an Associate Professor of Medicine and Genome Sciences at the University of Washington, where his research focuses on how alterations in the non-coding genome impact human health and disease, with a specific focus on rare non-coding variants that cause Mendelian conditions. To address this question, his laboratory develops and applies single-molecule chromatin fiber sequencing approaches to unravel the functional impact of non-coding genetic and epigenetic variants. In addition, he is an attending physician in the Medical Genetics clinic where he works with individuals with rare diseases.
Evgeny Kiner, PhD, is the founder of NeoSplice Therapeutics, an AI-driven biotechnology company that combines artificial intelligence, transcriptomics, and proteomics to identify disease-specific proteoforms as novel therapeutic targets. He is a trained RNA biologist and systems immunologist whose academic research helped establish single-cell RNA sequencing as a scalable approach for immune profiling. Prior to founding NeoSplice, he was a founding scientist at Immunai, where he helped develop AI-driven platforms for biological discovery.
